Clinical investigationOutcomes, Health Policy, and Managed CareCost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
Section snippets
Protocol
Effectiveness and resource utilization data were based on the results reported in the study4 and combined with additional resource utilization data obtained from a systematic review of the hospital records of patients included in this clinical study. Data included in this economic analysis were obtained from the 129 patients at 17 European centers enrolled in this study from January 1999 to September 2001.4 Resource utilization data items were length of hospitalization, general practitioner
Study patients
Of the 129 per-protocol patients in the clinical study, 125 were included in this economic assessment (61 in the iodixanol group and 64 in the iohexol group). Of these, 122 underwent coronary angiography with or without percutaneous coronary intervention, and 3 underwent peripheral angiography. It was not possible to collect resource utilization data for 4 patients, either because the investigators participating in the clinical study had left the centers (3 patients) or patient data were not
Discussion
In our study, cost-effectiveness analysis indicates that iodixanol had both lower costs and better effects when compared with iohexol in a high-risk population. The mean costs per patient for treating serious adverse drug reactions were significantly lower in the iodixanol than in the iohexol group (differences are €371, €399, and €445 for Sweden, Germany, and France, respectively, all with P < .01). Although contrast medium costs for the IOCM iodixanol were higher per patient than for the LOCM
References (31)
- et al.
Economic analysis of the use of contrast media during percutaneous coronary intervention (PCI) in France and Spain
Value Health
(2003) - et al.
Contrast nephropathy in patients with impaired renal function: high versus low osmolar media
Kidney Int.
(1992) - et al.
A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography
J. Am. Coll. Cardiol.
(1991) - et al.
Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study
Kidney Int.
(1995) - et al.
Complications and costs after high-risk surgery: where should we focus quality improvement initiatives?
J. Am. Coll. Surg.
(2003) - et al.
Contrast-media–induced nephrotoxicity: a consensus report. Contrast media safety committee, European Society of Urogenital Radiology (ESUR)
Eur. Radiol.
(1999) Nephrotoxicity related to contrast media
Scand. J. Urol. Nephrol.
(2000)- et al.
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention
Circulation
(2002) - et al.
Nephrotoxic effects in high-risk patients undergoing angiography
N. Engl. J. Med.
(2003) - et al.
Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography
N. Engl. J. Med.
(1992)
An economic analysis of strategies for the use of contrast media for diagnostic cardiac catheterization
Med. Decis. Making
Decision analysis to assess cost-effectiveness of low-osmolality contrast medium for intravenous urography
Am. J. Hosp. Pharm.
Iodixanol in cardioangiography in patients with coronary artery disease tolerability, cardiac and renal effects
Acta Radiol.
Iodixanol in abdominal digital subtraction angiography. A randomized, double-blind, parallel trial with iodixanol and iohexol
Acta Radiol.
Cited by (33)
Metallic nanoparticles as X-Ray computed tomography (CT) contrast agents: A review
2020, Journal of Molecular StructureCitation Excerpt :Since late 70s, X-ray contrast agents were used to enhance to contrast of the investigated region [9]. Various clinical contrast agents are available in the market pros and cons of which were detailed and studied by many researcher [10–14]. Today, X-ray computed tomography contrast agent market was dominated by iodine based contrast agents (IBCA) where thousands tons of IBCA were used every year [15,16].
46 Radiological contrast agents
2008, Side Effects of Drugs AnnualCitation Excerpt :The rate of nephrotoxicity in 100 consecutive patients with renal impairment undergoing multidetector row-computed tomography (MDCT) angiography with intravenous iodixanol 100 ml was 9%; all recovered renal function(16c). The cost-effectiveness of iodixanol was investigated in 125 patients at high risk of nephrotoxicity(17c). The analyses were based on a randomized, prospective, multinational comparison of the nephrotoxic effects of iodixanol with those of a low-osmolar non-ionic contrast medium, iohexol.
ACCF/AHA 2007 Clinical Competence Statement on Vascular Imaging With Computed Tomography and Magnetic Resonance.
2007, Journal of the American College of CardiologyCitation Excerpt :Physicians who wish to perform CTA must recognize that the presence of diabetes mellitus, pre-existing renal insufficiency, congestive heart failure, and recent contrast exposure significantly increase the risk of CIN (9–11). Practitioners must understand measures that may offer some protection against CIN such as hydration, discontinuation of nephrotoxic drugs, and the use of nonionic, iso-osmolar contrast agents (12–15). Severe anaphylactic reactions to contrast material are seen in 0.04% to 0.22% of procedures and can be life threatening (16).
Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography. The RECOVER Study: A Randomized Controlled Trial
2006, Journal of the American College of CardiologyCitation Excerpt :With the aging population and the incidence of diabetes increasing, older and sicker patients with serious renal and cardiovascular comorbidities now comprise a large proportion of those undergoing coronary angiography. Given this trend, the apparent clinical benefit shown for iodixanol versus ioxaglate here has important implications not only in terms of the potential for improved patient outcomes but also in terms of the potential for reduced health care costs in populations that traditionally have been associated with longer hospital stays and greater use of health care resources (25,26). In patients given greater doses of contrast media, iodixanol was also less likely to cause CIN than ioxaglate.
Economic evaluation of intravenous iodinated contrast media in Italy
2014, International Journal of Technology Assessment in Health CareRadiopacity Enhancements in Polymeric Implant Biomaterials: A Comprehensive Literature Review
2024, ACS Biomaterials Science and Engineering